Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Spark Therapeutics
WASHINGTON, May 19, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today that co-founder and scientific advisor Katherine High, M.D.; co-founder, president and CEO Jeffrey D. Marrazzo; and senior vice president of business development Carol Greve-Philips will each present at the American Society of Gene & Cell Therapy's (ASGCT) 2014 Annual Meeting.
Spark's team led the advancement of gene therapy research for nearly two decades-from designing and manufacturing vectors to conducting studies that have shown strong potential for safety and efficacy, building a recognized center of gene therapy innovation in research, translation and manufacturing. The company has a robust pipeline of clinical and preclinical gene therapy programs, and is currently advancing the only ongoing Phase 3 gene therapy study in the U.S. to address inherited retinal dystrophies caused by mutations of the RPE65 gene.
About Spark Therapeutics
Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the U.S., and the first treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.
Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. In addition to the Phase 3 program in RPE65-related blindness, the company has a Phase 1/2 program in hemophilia B and preclinical programs to address neurodegenerative diseases and other inherited retinal dystrophies and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company's expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark's team while at The Children's Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn more visit www.sparktx.com.
About the American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, www.asgct.org.
For information contact:
Feinstein Kean Healthcare
©2012 PR Newswire. All Rights Reserved.